Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC) by Baumann, M. & Grössmann, N.
  
Horizon Scanning 
in Oncology 
Pembrolizumab (Keytruda®) 
in previously treated advanced 
non-small cell lung cancer 
(NSCLC) 
 
 
DSD: Horizon Scanning in Oncology No. 58 
ISSN online 2076-5940 

  
Horizon Scanning 
in Oncology 
Pembrolizumab (Keytruda®) 
in previously treated advanced 
non-small cell lung cancer 
(NSCLC) 
 
Vienna, March 2016 
  
Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft  
 
Authors:  Martina Baumann, BSc, MSc  
Nicole Grössmann, BSc, MSc 
Internal review: Priv.-Doz. Dr. phil. Claudia Wild 
External review: PD Dr. Martin Früh 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited literature search.  
It is not a definitive statement on safety, effectiveness or efficacy and cannot replace professional medical advice nor 
should it be used for commercial purposes. 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals, developed within EUnetHTA 
(www.eunethta.eu) has been utilised when producing the contents and/or structure of this work. A working version 
(unpublished) of V3.0 of the Model was used. Use of the HTA Core Model® does not guarantee the accuracy, 
completeness, quality or usefulness of any information or service produced or provided by using the Model. 
 
 
 
 
CONTACT INFORMATION 
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for contents: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)  
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicise  
the research results of the Ludwig Boltzmann Institute of Health Technology Assessment. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at: 
http://eprints.hta.lbg.ac.at. 
DSD: Horizon Scanning in Oncology No. 58 
ISSN-online: 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2016 LBI-HTA – All rights reserved 
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC) 
LBI-HTA | 2016 3 
Table of Contents 
1 Research questions ............................................................................................................................................... 5 
2 Drug description .................................................................................................................................................. 6 
3 Indication .............................................................................................................................................................. 6 
4 Current regulatory status .................................................................................................................................... 6 
5 Burden of disease ................................................................................................................................................. 7 
6 Current treatment ................................................................................................................................................ 9 
7 Evidence ................................................................................................................................................................. 9 
7.1 Clinical efficacy and safety – phase III studies ........................................................................................ 10 
7.1.1 Clinical efficacy ...................................................................................................................................... 10 
7.1.2 Safety ........................................................................................................................................................ 12 
7.2 Clinical effectiveness and safety – further studies ................................................................................... 13 
8 Estimated costs ................................................................................................................................................... 14 
9 Ongoing research ................................................................................................................................................ 14 
10 Discussion ........................................................................................................................................................... 16 
11 References ............................................................................................................................................................ 18 
12 Appendix ............................................................................................................................................................. 20 
 
 
List of tables  
Table 1: Efficacy results of KEYNOTE-010 ............................................................................................................ 11 
Table 2: Safety result of KEYNOTE-010 – most frequent adverse events ............................................................ 13 
Table 3: Characteristics of the KEYNOTE-010 trial .............................................................................................. 20 
 
 
 

Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC) 
LBI-HTA | 2016 5 
1 Research questions 
The EUnetHTA HTA Core Model® for Rapid Relative Effectiveness Assess-
ment of Pharmaceuticals was used for structuring this report [1]. The Model 
organises HTA information according to pre-defined generic research ques-
tions. Based on these generic questions, the following research questions were 
answered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is pembrolizumab? 
A0022 Who manufactures pembrolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has pembrolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC for the patient? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of pembrolizumab on mortality? 
D0005 How does pembrolizumab affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does pembrolizumab affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of pembrolizumab on patients´ body functions? 
D0012 What is the effect of pembrolizumab on generic health-related quality of life? 
D0013 What is the effect of pembrolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is pembrolizumab in relation to docetaxel? 
C0002 Are the harms related to dosage or frequency of applying pembrolizumab? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of pembrolizumab? 
A0021 What is the reimbursement status of pembrolizumab? 
 
 
 
 
EUnetHTA HTA  
Core Model®  
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2 Drug description 
Generic/Brand name/ATC code:  
Pembrolizumab/MK-3475/Keytruda®/L01XC18 
 
B0001: What is pembrolizumab? 
Pembrolizumab (Keytruda®) is a humanised monoclonal anti-programmed 
cell death-1 (PD-1) antibody (lgG4/kappa isotype with a stabilising sequence 
alteration in the Fc region), which is produced in Chinese hamster ovary cells 
by recombinant DNA technology [2]. It binds to an inhibitory signalling re-
ceptor (PD-1) on the surface of activated T cells and blocks the binding of lig-
ands which negatively regulate the activation of T cells and thus play an im-
portant role in tumour evasion from host immunity [3]. 
The recommended dose of pembrolizumab is 2mg/kg administered as an in-
travenous (IV) infusion over 30 minutes every three weeks; treatment should 
be continued until disease progression or unacceptable toxicity occurs. In case 
of atypical responses, like an initial transient increase in tumour size or small 
new lesions within the first few months followed by tumour shrinkage, it is 
recommended to continue treatment in clinically stable patients until disease 
progression gets confirmed [2]. 
 
A0022: Who manufactures pembrolizumab? 
Merck Sharp & Dohme  
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Pembrolizumab (Keytruda®) is indicated for metastatic non-small cell lung 
cancer (NSCLC) in previously treated patients with PD-L1 expressing tumours.  
 
 
 
4 Current regulatory status 
A0020: For which indications has pembrolizumab received  
marketing authorisation? 
The European Medicines Agency (EMA) granted a marketing authorisation 
valid throughout the European Union for pembrolizumab on 17 July 2015 for 
the indication of unresectable or metastatic melanoma [2]. 
anti-PD-1 antibody, 
immune checkpoint 
inhibitor 
2mg/kg administered IV 
every 3 weeks 
indicated for pretreated 
NSCLC patients  
approved for NSCLC by 
FDA but not by EMA 
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The US Food and Drug Administration (FDA) granted marketing authori-
sation for pembrolizumab for the following indications: 
 for the treatment of patients with advanced or unresectable melanoma 
no longer responding to other drugs (September 2014)[4]. 
 for the treatment of patients with metastatic NSCLC whose tumours 
express PD-L1 as determined by an FDA-approved test (PD-L1 IHC 
22C3 pharmDx assay) and who have disease progression on or after 
platinum-containing chemotherapy. In addition, pembrolizumab is al-
so approved for pts with EGFR or ALK genomic tumour aberrations 
in which the disease has progressed under prior therapy (October 2015). 
Pembrolizumab has been licensed under the accelerated scheme based 
on tumour response rate and durability of response (based on phase Ib 
KEYNOTE-001 study), whilst an improvement in survival or disease-
related symptoms hast not yet been established [5]. 
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common type of lung cancer which accounts for about 
85%–90% of all lung cancers. Two major types of NSCLC can be distin-
guished histologically: non-squamous and squamous cell (epidermoid) car-
cinoma. About 22% of NSCLCs are squamous cell carcinomas which are 
characterised by the presence of keratin production by tumour cells and/or 
intercellular desmosomes (“intercellular bridges”) [6, 7]. After histological 
evaluation, the cancer can be staged according to the Tumour Node Metas-
tasis (TNM) to further characterise cancer severity. The TNM system groups 
lung cancer into 4 stages, based on the size of the tumour and presence or 
absence of nodal and distant metastases [6]. NSCLC is a heterogeneous group 
of diseases. Although the initial treatment of localised disease is the same, 
the molecular characterisation of the disease, also in terms of driver muta-
tions (EGFR, ALK), has become increasingly important for prognosis and 
choice of therapy in the last few years [8]. 
 
A0004: What is the natural course of NSCLC? 
Patients with lung cancer are usually diagnosed at a late stage of disease since 
symptoms do not manifest until the tumour is locally advanced or there is 
metastatic disease. The median age at diagnosis for lung cancer is about 70 
years [9]. Besides the stage of the disease, prognostic factors include Euro-
pean Cooperative Oncology Group (ECOG) Performance Status, gender and 
weight loss, and mutational status [8, 10]. In Germany, only 21% of women 
and 16% of men with lung cancer are alive 5 years after diagnosis [11]. Pa-
tients at early stages survive for a median of 59 months, whereas patients with 
advanced stage IV disease have a life expectancy of about 4 months. In Aus-
tria, of newly diagnosed lung cancer patients, 34% of tumours were dissemi-
nated.  
 
advanced or 
unresectable melanoma  
metastatic NSCLC 
 
licensed under the 
accelerated scheme 
NSCLC accounts for  
85-90% of all lung 
cancers  
 
subtypes: squamous  
& non-squamous 
 
 
 
 
various driver mutations 
are known 
late diagnosis and low  
5-year survival rate 
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A0006: What are the consequences of NSCLC for the society? 
Primary lung cancer is the leading cause of cancer deaths worldwide. While 
the mortality of lung cancer is declining in men, increasing rates in women 
have been observed in Europe [12]. In Austria, 4,573 patients were newly di-
agnosed with lung cancer in 2012 equalling an incidence rate of 30.5 cases 
per 100,000 persons. 3,673 patients died from lung cancer in 2012. The age-
standardised incidence and mortality rates are about twice as high for men 
(32.8) than for women (15.8) [13]. On average, patients are aged 70 years at 
the time of diagnosis of NSCLC [14]. 
 
A0023: How many people belong to the target population? 
The target population for the treatment with pembrolizumab is defined as 
patients with advanced and metastatic NSCLC with positive PD-L1 status. 
Positive PD-L1 status has an incidence of 25–30% in NSCLC patients [15].  
 
A0005: What are the symptoms and the burden of NSCLC for the patient? 
Cough, haemoptysis, chest pain, dyspnoea or hoarseness may be indicative of 
lung cancer. NSCLC symptoms also include significant weight loss and fa-
tigue [16]. 
 
A0003: What are the known risk factors for NSCLC? 
The main risk factor for NSCLC is smoking. Other known risk factors are 
radiation therapy and environmental toxins such as second-hand smoke, as-
bestos, arsenic, and polycyclic aromatic hydrocarbons [12]. 
 
A0024: How is NSCLC currently diagnosed according  
to published guidelines and in practice? 
For diagnosis and staging, it is recommended to take a first-imaging chest x-
ray followed by a computerised tomography (CT) scan. A clinical history in-
cluding smoking history, a physical exam and laboratory tests are required as 
well. To further characterise the tumour’s pathology, small biopsy samples 
should be taken and cytology should be performed; immune-histochemical 
staining (IHC) serves to differentiate the cancer histologically. Since the pres-
ence of specific genetic mutations – i.e. mutations in the epidermal growth 
factor receptor (EGFR) and rearrangements of the anaplastic lymphoma ki-
nase (ALK) genes – enables administration of targeted therapies, patients 
with non-squamous NSCLC should be tested for EGFR mutations and ALK 
rearrangements before the initiation of first-line treatment. Due to the low 
incidence of these mutations in patients with squamous-cell NSCLC, testing 
of these mutations is not recommended in Europe, the only exception being 
people who never smoked or people who are former light smokers [10, 12]. 
The PD-L1 IHC 22C3 pharmDx assay should be used to identify PD-L1 ex-
pression [17]. 
 
 
 
incidence rate in 
Austria: 30.5 per 
100,000 persons 
PD-L1 positive patients, 
25% of all NSCLC 
main risk factor: 
smoking 
diagnosis: 
x-ray & CT 
 
 
 
IHC for molecular 
characterisation 
diagnosis of  
PD-L1 status with  
IHC test 
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6 Current treatment 
A0025: How is NSCLC currently managed according  
to published guidelines and in practice? 
The most commonly used treatment modalities for NSCLC are radiation ther-
apy, surgery and systematic therapy. Depending on the tumour stage, histol-
ogy (non-squamous or squamous), presence or absence of driver mutations 
and the overall medical condition of a patient, these treatments can be ap-
plied alone or in combination [18, 19]. 
Tumour tissue should be assessed for the presence of a driver mutation (EGFR, 
ALK). If there is no driver mutation present in the tumour of a patient, the 
initial treatment utilises four to six cycles of cytotoxic chemotherapy with a 
platinum-based doublet. Supplementary bevacizumab can be used in patients 
with non-squamous NSCLC. For patients who are responding or stable after 
initial treatment, maintenance therapy can be considered. Therapy options are 
bevacizumab, single-agent chemotherapy or an EGFR inhibitor (afatinib or 
erlotinib) in patients with an activating mutation of EGFR. For patients with 
the ALK fusion oncogene or ROS1 translocations, crizotinib may be applied 
[18].  
If patients with advanced NSCLC developing a progressive disease after pre-
vious treatment, subsequent therapy is required. Therefore, several factors 
need to be taken into account including molecular characteristics of the tu-
mour, performance status and the type of prior treatment. Immune check-
point inhibitors such as nivolumab are preferred treatment options for the 
subsequent therapy of patients with metastatic NSCLC pretreated with a 
chemotherapy regimen. Osimertinib is a therapy option for patients with an 
activating mutation of EGRF who have progressed after erlotinib, afatinib or 
geftinib. Treatment of progressive disease with an ALK rearrangement or sen-
sitising EGFR mutations is dependent on whether the progression is asymp-
tomatic or symptomatic [18, 19].  
 
 
 
7 Evidence 
A literature search was conducted on 28 January 2016 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Pembrolizumab”, “Keytruda”, “Lambrolizumab”, “mk-
3475”, “non-small cell lung cancer” and “NSCLC”. The manufacturer was 
contacted for additional information on completed and ongoing trials. Man-
ual search identified 15 additional references (web documents and journal ar-
ticles). 
Overall, 223 references were identified. The manufacturer sent no unpub-
lished data, only information about ongoing trials as can be found on clini-
caltrials.gov.  
Included in this report is one phase III study, KEYNOTE-010.  
most commonly  
used treatments:  
radiation therapy,  
surgery and 
systematic therapy 
assessing the presence 
of a driver mutation: 
EGFR or ALK 
molecular  
characteristics, 
performance status & 
prior treatment have to 
be taken into  
account for subsequent 
therapy 
systematic search in  
5 databases:  
223 references 
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7.1 Clinical efficacy and safety  
– phase III studies 
KEYNOTE-010 (NCT01905657) is a randomised, open-label, phase II/III mul-
ticentre study with 1,034 previously treated patients with advanced NSCLC. 
Patients were stratified by ECOG status, region and PD-L1 expression (1-49% 
vs ≥50% expression) and received either pembrolizumab 2mg/kg or pem-
brolizumab 10mg/kg or 75mg/m2 docetaxel intravenously over 1 hour every 
3 weeks. Primary endpoints were progression-free survival (PFS) and overall 
survival (OS), secondary outcomes were response rate (RR) and adverse events 
(AEs).  
All patients had a histologically or cytologically confirmed diagnosis of NSCLC 
that was PD-L1 positive per central laboratory review. 43% had a PD-L1 ex-
pression of at least 50%. Almost all patients had an Eastern Cooperative On-
cology Group (ECOG) Performance Status of 0 or 1 and the median age was 
63 years.  
Histology of tumours was in 70% of cases non-squamous and 8% had an 
EGFR mutation. Median follow-up at the time of data cut-off (30 September 
2015, 2 months after the prespecified second interim analysis) was 13.1 months. 
521 of 1,034 patients had died: 50% in the pembrolizumab 2mg/kg group, 45% 
in the pembrolizumab 10mg/kg group, and 56% in the docetaxel group. After 
discontinuation of study treatment, additional antineoplastic treatment was 
received by 40%, 38% and 44% respectively. 
For detailed patient characteristics including inclusion and exclusion crite-
ria, please see the appendix, efficacy data can be found in Table 1 and AEs 
are listed in Table 2.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect  
of pembrolizumab on mortality? 
In patients with a PD-L1 tumour proportion score of 50% or greater3, the 
hazard ratio (HR) for overall survival for pembrolizumab 2 (10) mg/kg ver-
sus docetaxel was 0.54 (0.50). Median OS was 14.9 months for the pembroli-
zumab 2mg/kg group, 17.3 months for the pembrolizumab 10mg/kg group, 
and 8.5 months for the docetaxel group [20]. 
In the total population, median OS was 10.4 (pembrolizumab 2mg/kg), 12.7 
(pembrolizumab 10mg/kg) and 8.5 months (docetaxel). HR of OS was 0.71 for 
pembrolizumab 2mg/kg vs docetaxel and 0.61 for 10mg/kg pembrolizumab 
vs docetaxel [20]. 
 
                                                             
1 pembro. 2mg = pembrolizumab 2mg/kg 
2 pembro. 10mg = pembrolizumab 10mg/kg 
3 tumour proportion score of 50% or greater = PD-L1 expression on at least 50% of 
tumour cells 
Keynote-010 (phase 
II/III trial) compared 
pembrolizumab to 
docetaxel in previously 
treated patients with 
advanced NSCLC  
median follow-up  
13.1 months 
 
discontinuation of 
treatment: 
 
docetaxel: 40% 
 
pembro. 2mg/10mg: 
38%/44% 
median OS in months 
docetaxel: 8.5 
PD-L1 ≥50%: 
pembro. 2mg1: 14.9 
pembro. 10mg2: 17.3 
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D0006: How does pembrolizumab affect progression  
(or recurrence) of NSCLC? 
In patients with a PD-L1 tumour proportion score of 50% or greater, pem-
brolizumab increased median PFS from 4.1 months (docetaxel) to 5.0 (5.2) 
months (pembrolizumab 2 (10) mg/kg). The HR of PFS for both doses of pem-
brolizumab vs docetaxel was 0.59 [20]. For the total population, there was no 
statistically significant difference in PFS between the treatment groups.  
 
D0005: How does pembrolizumab affect symptoms and findings  
(severity, frequency) of NSCLC? 
All responses were partial responses. Response rates were 30% (pembrolizum-
ab 2 mg/kg), 29% (pembrolizumab 10 mg/kg), and 8% (docetaxel) in patients 
with a PD-L1 ≥50% score. In the total population, pembrolizumab increased 
response rates in comparison with docetaxel from 9% to 18%, irrespective of 
dosage [20]. 
 
D0011: What is the effect of pembrolizumab on patients’ body functions? 
D0012: What is the effect of pembrolizumab on  
generic health-related quality of life? 
D0013: What is the effect of pembrolizumab on disease-specific quality of life? 
No evidence was found for effects of pembrolizumab on body functions and 
on generic health-related quality of life or disease-specific quality of life.  
Table 1: Efficacy results of KEYNOTE-010 
Descriptive 
statistics and 
estimated 
variability4 
Treatment group Pembro. 
2mg/kg 
Pembro. 
10mg/kg 
Docetaxel 
75mg/m² 
Pembro. 
2mg/kg 
Pembro. 
10mg/kg 
Docetaxel 
75mg/m² 
Total population PD-L1 ≥50% 
Number of subjects 344 346 343 139 151 152 
OS median (95% Cl), 
months 
10.4  
(9.4–11.9) 
12.7  
(10.0–17.3) 
8.5  
(7.5–9.8) 
14.9 (10.4–
NR) 
17.3  
(11.8–NR) 
8.2  
(6.4–10.7) 
1 year OS,% 43.2 52.3 34.6 NA NA NA 
PFS median (95% Cl), 
months 
3.9  
(3.1–4.1) 
4.0  
(2.7–4.3) 
4.0  
(3.1–4.2) 
5.0 
(4.0–6.5) 
5.2 
(4.1–8.1) 
4.1 
(3.6–4.3) 
Grade 3–5 AEs,% 13 16 35 13 16 35 
Median time to 
response (all partial) 
9 weeks 9 weeks 9 weeks 9 weeks 9 weeks 9 weeks 
Response,% 18 18 9 30 29 8 
Median duration  
of response 
NR NR 6 months NR NR 8 months 
 
                                                             
4 At the time of data cutoff, which was after the second interim analysis, 521 patients 
had died.   
median PFS in months 
docetaxel: 4.1 
pembro. 2mg1: 5.0 
pembro. 10mg2: 5.2 
partial responses 
increased 
no evidence:  
body functions, QoL 
Horizon Scanning in Oncology 
12 LBI-HTA | 2016 
Effect 
estimate per 
comparison 
Comparison groups  Pembro. 
2mg/kg vs. 
docetaxel 
Pembro. 
10mg/kg vs. 
docetaxel 
Pembro. 
2mg/kg vs. 
docetaxel 
Pembro. 
10mg/kg vs. 
docetaxel 
Total population PD-L1 ≥50% 
OS HR 0.71 0.61 0.54 0.50 
95% CI 0.58–0.88 0.49–0.75 0.38–0.77 0.36–0.70 
p value 0.0008 <0.0001 0.0002 <0.0001 
PFS HR 0.88 0.79 0.59 0.59 
95% CI 0.74–1.05 0.66–0.94 0.44–0.78 0.45–0.78 
p value 0.07 0.004 0.0001 <0.0001 
Abbreviations: AE = adverse event, CI = confidence interval, ECOG = Eastern Cooperative Oncology Group,  
HR = hazard ratio, NA = not available, NR = not reached, OS = overall survival, PD-L1 = programmed death ligand 1, 
Pembro. = pembrolizumab, PFS = progression-free survival, RECIST = Response Evaluation Criteria In Solid Tumours 
 
7.1.2 Safety 
C0008: How safe is pembrolizumab in relation to docetaxel? 
Grade 3–5 treatment-related adverse events were less common in the pem-
brolizumab groups than in the docetaxel group. In the KEYNOTE-010 study, 
13% of patients given 2 mg/kg and 16% of patients given 10 mg/kg pembroli-
zumab vs 35% of patients given docetaxel showed these high-grade AEs [20]. 
A detailed list of all AEs related to treatment in the KEYNOTE-010 study is 
shown in Table 2.  
 
C0002: Are the harms related to dosage or frequency  
of applying pembrolizumab? 
Higher dosage of pembrolizumab (10 mg/kg) increased the frequency of AEs 
grade 3–5 from 13% to 16% [20]. 
 
C0005: What are the susceptible patient groups  
that are more likely to be harmed through use of pembrolizumab? 
Older and frailer patients with more severe symptoms and comorbidities may 
be assumed to have more severe side effects than reported in the studies, 
which only included patients with an ECOG status of 0 or 1 [21]. 
Pembrolizumab belongs to the new class of immune targeting therapies which 
have a unique side-effect profile due to off-target effects on the immune sys-
tem function [22]. Patients with a compromised immune system or autoim-
mune diseases have been excluded from the study population, probably be-
cause more severe side effects may be expected in this group. 
AEs grade 3–5 
docetaxel: 35% 
pembro. 2mg1: 13% 
pembro. 10mg2: 16% 
patient groups older and 
comorbid patients 
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Table 2: Safety result of KEYNOTE-010 – most frequent adverse events 
Adverse event  
(according to NCI-CTC version 4.0) 
Pembrolizumab 2mg/kg 
(n = 339) 
Pembrolizumab 10mg/kg 
(n = 343) 
Docetaxel  
(n = 309) 
 Any grade Grade 3–5 Any grade Grade 3–5 Any grade Grade 3–5 
Related to treatment, %5 
Any 63 13 66 16 81 35 
Occurring in ≥ 10% of patients in any study group, % 
Decreased appetite 14 1 10 <1 16 1 
Fatigue 14 1 14 2 25 4 
Nausea 11 <1 9 1 15 <1 
Rash 9 <1 13 <1 5 0 
Diarrhoea 7 1 6 0 18 2 
Asthenia 6 <1 6 1 11 2 
Stomatitis 4 0 2 <1 14 1 
Anaemia 3 1 4 <1 13 2 
Alopecia 1 0 1 0 33 1 
Neutropenia <1 0 <1 0 14 12 
Adverse event of special interest, %  
(occurring in ≥ 2 patients in the pembrolizumab groups) 
Hypothyroidism 8 0 8 0 <1 0 
Pneumonitis 5 2 4 2 2 1 
Hyperthyroidism 4 0 6 <1 1 0 
Colitis 1 1 1 <1 0 0 
Severe skin reactions 1 1 2 2 1 1 
Pancreatitis 1 1 0 0 0 0 
Adrenal insufficiency 1 0 1 <1 0 0 
Myositis 1 0 <1 0 <1 0 
Thyroiditis 1 0 0 0 0 0 
Autoimmune hepatitis <1 <1 1 0 0 0 
Hypophysitis <1 <1 <1 <1 0 0 
Type 1 diabetes <1 <1 1 <1 0 0 
 
 
7.2 Clinical effectiveness and safety – further studies 
NCT01295827 (P07990/MK-3475-001/KEYNOTE-001) [23] is a phase I study 
of pembrolizumab in participants with progressive, locally advanced or met-
astatic carcinoma, melanoma, or NSCLC and will be completed in July 2016. 
It led to the FDA approval of pembrolizumab for NSCLC. 80% of the 495 
patients had received prior therapy. They received varying doses of pembroli-
zumab IV, every two or three weeks, until disease progression. 
Across doses, schedules, and degrees of PD-L1 expression, the overall response 
rate (ORR, assessed per RECIST v1.1) was 19.4%, median duration of response 
was 12.5 months and median OS was 12 months. Patients with previous treat-
ment had lower duration of median response and response rates (10 vs. 23 
months and 18 vs. 25%) and lower median OS (9.3 vs. 16 months) [23].  
                                                             
5 Assessed by the investigator 
approval of 
pembrolizumab for 
NSCLC based on 
KEYNOTE-001  
(phase Ib trial) 
safety and efficacy  
in KEYNOTE-001  
ORR 19.4% 
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A relationship between the degree of PD-L1 expression and efficacy outcomes 
was found. Patients with PD-L1 expression in ≥50% of tumour cells had 
higher ORR and longer PFS and OS compared with patients who had PD-L1 
expression in <50% of tumour cells. PD-L1 prevalence was established by 
screening patients with advanced NSCLC. 23.2% of 824 patients had ≥50% 
expression. The trial was amended after the first NSCLC cohort to require 
tumour PD-L1 expression by immunohistochemistry (≥1% of tumour cells 
staining for PD-L1 using the Dako 22C3 PD-L1 assay) for all, but one of the 
subsequent NSCLC expansion cohorts. Thus, the majority of patients treated 
had some degree of tumour PD-L1 expression. 
Another result was that previous or current smokers had an ORR of 22.5% 
compared with 10.3% in non-smokers.  
The most common low-grade toxicities were fatigue, pruritus and decreased 
appetite. Grade 3 or higher toxicities occurred in 10% of patients [23, 24]. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of pembrolizumab? 
The recommended dose of pembrolizumab is 2 mg/kg administered every 3 
weeks [2]. Pembrolizumab (Keytruda®) is available as a powder for injection 
solutions, 50 mg cost € 1,812.55 [25]. Assuming an average body weight of 70 
kg, 140 mg pembrolizumab would be needed, costing € 5,075.14 every three 
weeks. 
 
 
 
9 Ongoing research 
Numerous trials (47 registered in clinicaltrials.gov, search terms “pembroli-
zumab” and “NSCLC”) in patients with NSCLC are ongoing, which evaluate 
pembrolizumab as a single agent or in combination and as first-line or sec-
ond-line treatment. Comparators are either placebo or docetaxel and PD-L1-
expression is an inclusion criterion in several the studies. All KEYNOTE 
studies and all phase III studies are sponsored by Merck.  
Selection of phase I and II studies: 
 NCT01840579 (MK-3475-011/KEYNOTE-011): A phase I study of 
pembrolizumab alone in subjects with advanced solid tumours and in 
combination with cisplatin/pemetrexed or carboplatin/paclitaxel in 
subjects with advanced NSCLC, estimated completion June 2016. 
 NCT02039674 (MK-3475-021/KEYNOTE-021): A Phase I/II study of 
pembrolizumab in combination with chemotherapy or immunothera-
py in patients with locally advanced or metastatic NSCLC, estimated 
completion June 2019. 
grade 3–5 toxicities in 
10% of patients 
estimated costs 
€ 5,075.14 every 3 weeks 
47 ongoing trials 
registered in 
clinicaltrial.gov 
MSD-sponsored  
phase I/II trials 
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 NCT02007070 (MK-3475-025/KEYNOTE-025): An open-label, non-
randomised, multicentre phase Ib study of pembrolizumab in subjects 
with PD-L1 positive advanced NSCLC, estimated completion Septem-
ber 2016. 
 NCT02564380: A phase II randomised, double-blind, placebo-con-
trolled study of pembrolizumab maintenance following first-line plati-
num-based chemotherapy in patients with metastatic squamous NSCLC, 
estimated completion September 2019. 
 NCT02343952: An open-label, multi-institutional, single-arm phase II 
trial of consolidation therapy with pembrolizumab, following initial 
treatment with concurrent chemoradiation in patients with inoperable 
or unresectable stage IIIA or IIIB NSCLC. No randomisation or blind-
ing, estimated completion January 2017. 
 NCT02574598 (sponsored by Instituto Nacional de Cancerologia de 
Mexico): A phase II open-label randomised clinical trial of pembroli-
zumab in combination with docetaxel vs docetaxel alone on previous-
ly treated PD-L1 positive NSCLC patients, estimated completion Oc-
tober 2020.  
Selection of phase III studies: 
 MK-3475-042/KEYNOTE-042: A randomised, open-label phase III 
study comparing overall survival of pembrolizumab versus platinum-
based chemotherapy in treatment-naive subjects with PD-L1 positive 
advanced or metastatic non-small cell lung cancer, estimated comple-
tion July 2019. 
 MK-3475-024/KEYNOTE-024: A randomised open-label phase III tri-
al of pembrolizumab versus platinum-based chemotherapy in 1L sub-
jects with PD-L1 strong metastatic non-small cell lung cancer, estimat-
ed completion May 2018. 
 MK-3475-091/KEYNOTE-091: A randomised phase III trial with pem-
brolizumab versus placebo for patients with early-stage NSCLC after 
resection and completion of standard adjuvant therapy (PEARLS), es-
timated completion April 2024. 
 MK-3475-189/KEYNOTE-189: A randomised, double-blind phase III 
study of platinum + pemetrexed chemotherapy with or without pem-
brolizumab in first-line metastatic non-squamous NSCLC subjects, es-
timated completion March 2019.  
 
 
  
1 independent trial 
comparing 
pembrolizumab + 
docetaxel vs docetaxel 
4 RCTs 
sponsored by MSD 
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10 Discussion 
Pembrolizumab 2 mg/kg given once every 3 weeks was granted accelerated 
approval in the USA for the treatment of patients with metastatic NSCLC, 
whose tumours express PD-L1 (tested by means of PD-L1 IHC 22C3 pharm-
Dx assay) with disease progression during or after platinum-containing chem-
otherapy. This approval was based on a multicohort, phase Ib study, KEY-
NOTE-001. Up to now, data from only one further study, the phase III KEY-
NOTE-010 study, is available. The EMA granted marketing authorisation to 
pembrolizumab, but so far the sole indication is for patients with unresectable 
or metastatic melanoma [2]. 
KEYNOTE-010 [20], a randomised, open-label phase II/III study, was con-
ducted to compare two different dosages of pembrolizumab with docetaxel 
in a total of 1,034 previously treated patients with PD-L1 positive, advanced 
NSCLC. The efficacy results showed an improvement in median OS in all pa-
tients treated with pembrolizumab compared to docetaxel; whereas the high-
est gains in median OS were achieved by patients with a tumour proportion 
score of ≥50% (median OS gain: 6.7 (2mg) and 9.1 (10mg) months). PFS with 
pembrolizumab was superior to that of docetaxel in patients with a tumour 
proportion score of ≥50% (median PFS gain: 0.9 (2mg) and 1.1 (10mg) months) 
but not in the total population. AEs related to pembrolizumab were lower than 
for docetaxel.  
Although there was a statistically significant improvement in median OS in 
the total population, it was much smaller (median OS gain: 2.1 months for 
the recommended dosage 2 mg/kg; 4.2 months for dosage 10 mg) than in the 
subpopulation of patients with a tumour proportion score ≥50%. The iden-
tification of PD-L1 positive patients will thus be crucial for meaningful ben-
efits in an average clinical setting. 
It should be noted that there was no significant difference in OS results for 
the EGFR-mutant subgroup (86 patients) between the study groups. In addi-
tion, concerning the PFS results, a trend favouring docetaxel over pembroli-
zumab treatment could be observed for this group. Since these results are 
based on a relatively small patient sample, the best choice of treatment for 
patients with EGFR mutations cannot be concluded from these results. 
Limitations of the study may exist in regard to generalizability, as median 
patient age was 63 and almost all patients had an ECOG score of <2. Patients 
are aged about 70 years at the time of diagnosis of NSCLC and the target pop-
ulation includes also patients with a higher ECOG score [14]. For these ex-
cluded patient groups side-effects and efficacy might be different. 
Another concern is that there is no quality of life (QoL) data available. Pem-
brolizumab causes fewer side effects than docetaxel, but without an assess-
ment of the general or disease-specific quality of life, it is problematic to state 
that pembrolizumab has a favourable benefit for patients compared to exist-
ing therapies, especially as other immunotherapies against NSCLC, like niv-
olumab, are not considered in the study.  
One methodological limitation of the KEYNOTE-010 study is that it is an 
open-label trial, so neither patients nor clinicians have been blinded. How-
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ever, PFS was the only reported outcome dependent on subjective evaluation, 
and it was assessed by an independent central review. Bias may, however, 
have been introduced in the safety assessment, as this was carried out by the 
non-blinded investigator.  
After discontinuation of treatment, additional antineoplastic treatment was 
received by 40%/38% in the two pembrolizumab groups and 44% in the doce-
taxel group, but it was not reported for what reasons and at which time point 
[26]. It has been argued that a discontinuation number should be included 
in the Kaplan-Meier analysis, which was not done in this study. A bias could 
have been introduced, if discontinuation and ensuing censoring differed in 
the study groups. For example, discontinuation in the docetaxel group could 
have been primarily due to side effects and in the pembrolizumab group due 
to missing response, leading to an overestimation of response to pembroli-
zumab. Also, OS results may have been influenced by therapies that followed 
after discontinuation [27].  
Furthermore, the utility of PD-L1 as a biomarker of response is compromised 
by technical issues and the dynamic, inducible expression of PD-L1, which 
may also differ between solid tumours and metastatic sites [28]. Taking oth-
er studies into account, RR is clearly higher in the PD-L1 expressing pa-
tients, but the predictive and prognostic value of PD-L1 expression for OS is 
less clear [15]. Questions also remain in regard to the exact cut-off value of 
PD-L1-expression, its clinical implementation and alternative or additional 
subgroup markers. Quantifying smoking history by number of pack-years of 
consumption may prove to be just as sensitive an indicator of benefit as PD-
L1 expression since there is a significant difference in response rate between 
smokers and non-smokers (27% vs 9%) [15]. To identify the patients that ben-
efit from pembrolizumab, a biopsy of the patient’s tumour has to be availa-
ble and a standardised, validated test has to be applied.  
Costs are difficult to estimate, as they depend not only on the cost of pem-
brolizumab dosage and treatment duration. Treatment of side-effects, savings 
of costs for symptomatic treatment in case of better overall constitution of 
patients, costs for screening/testing of PD-L1 expression and costs for alter-
native treatments have to be additionally taken into account. No estimates 
exist for the overall cost-effectiveness of pembrolizumab yet. 
Targeting of the PD-L1 checkpoint blockade is a potential new option for pre-
viously treated, advanced NSCLC patients. However, it should be noted that 
approval by the FDA is based on preliminary results from a phase Ib trial. 
The new findings from the phase III KEYNOTE-010 trial have to be consid-
ered for decisions about the future application of pembrolizumab in NSCLC 
patients, and more studies with long-term data are needed. 
KEYNOTE-010 reports superior efficacy (OS, PFS and RR) with fewer side 
effects for PD-L1 positive patients, defined as an expression of ≥50% by 
means of an FDA-specified test compared to docetaxel. Besides the challenge 
of defining a PD-L1 expression cut-off value or other predictive biomarkers 
for response, and technical issues in regard to PD-L1 testing, generalisability 
is unclear as only relatively young patients with an ECOG of 0 or 1 have been 
included in the KEYNOTE-010 trial. Additionally, the benefit for patients 
with an EGFR mutation has to be further examined. Patient-relevant out-
comes (such as QoL) are still missing but shall be measured in an ongoing 
trial. Also, the evaluation of safety and efficacy of combination therapies is 
ongoing. 
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12 Appendix 
Table 3: Characteristics of the KEYNOTE-010 trial 
Title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer [20] 
Study identifier NCT01905657, 2012-004391-19, KEYNOTE-010 
Design Randomised, open-label, international phase II/III study 
Duration Enrolment: 2013-08-28 to 2015-02-27 
Median follow-up (at the time of data cut-off 2015-09-30):  
13.1 months (IQR 8.6–17.7) 
Cut-off dates for analyses: first interim analysis: Nov 2014, 
second interim analysis: Jul 2015 
Hypothesis With 140 deaths between one MK-3475 arm and control, the study has over 
81% power to detect a 0.55/0.70 hazard ratio for overall survival in the population of patients with a 
tumour proportion score of 50% or greater/in the total population at the final analysis, where 0.825% 
alpha is allocated to the two MK-3475 vs. docetaxel comparisons using the Hochberg procedure. 
Funding  Merck Sharp & Dohme 
Treatments 
groups 
Intervention (n = 345) Pembrolizumab 2 mg/kg every 3 weeks 
Intervention (n = 346) Pembrolizumab 10 mg/kg every 3 weeks 
Control (n = 343) Docetaxel 75 mg/m² every 3 weeks  
Endpoints and 
definitions 
Progression-free survival 
(primary endpoint) 
PFS Defined as the time from randomisation to documented disease 
progression according to RECIST or death from any cause 
Overall survival 
(primary endpoint) 
OS Defined as the time from randomisation to death  
from any cause 
Response rate RR Percentage of patients with complete or partial response 
according to RECIST (version 1.1) 
Safety - - 
Results and analysis  
Analysis 
description 
Efficacy was assessed in the intention-to-treat-population. 
Safety was assessed in patients who received at least one dose of study treatment 
Analysis 
population  
Inclusion  Life expectancy of at least 3 months 
 Age ≥ 18 years 
 Histologically or cytologically confirmed diagnosis of NSCLC that is PD-L1 positive 
(≥ 1% of tumour cells) per central laboratory review 
 At least one bi-dimensional measurable lesion 
 Radiographic progression after treatment with at least 2 or more cycles of a 
platinum-containing doublet 
 Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 
Exclusion  Prior therapy with PD-1 checkpoint inhibitors or docetaxel  
 Receiving systemic steroid therapy within three days prior to the first dose of study 
treatment or receiving any other form of immunosuppressive medication 
 Currently participating or having participated in a study using an investigational 
antineoplastic agent or device within 30 days of first dose 
 Expected to require any other form of systemic or localised antineoplastic therapy 
while on trial 
 History of allogeneic tissue/solid organ transplant 
 Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g. 
cetuximab), major surgery within 3 weeks of the first dose of study drug; received 
thoracic radiation therapy of >30 Gray within 6 months of the first dose of study 
drug; received prior tyrosine kinase inhibitor therapy or completed palliative 
radiotherapy within 7 days of the first dose of study drug 
 Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, 
anti-tumour necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug 
specifically targeting T-cell co-stimulation or checkpoint pathways or participation 
in a previous pembrolizumab trial  
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Title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer [20] 
Study identifier NCT01905657, 2012-004391-19, KEYNOTE-010 
Analysis 
population  
(continuation) 
Exclusion  Known history of prior malignancy, with the exception of basal cell carcinoma of 
the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ 
cervical cancer, and has undergone potentially curative therapy with no evidence 
of disease recurrence for 5 years since initiation of that therapy 
 Known active central nervous system (CNS) metastases and/or carcinomatous 
meningitis 
 Active autoimmune disease, or a documented history of autoimmune disease,  
or a syndrome that requires systemic steroids or immunosuppressive agents 
 Interstitial lung disease, or history of pneumonitis requiring systemic steroids  
for treatment 
 Known history or active human immunodeficiency virus (HIV), hepatitis B or 
hepatitis C 
 Pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the trial through 120 days after last dose of pembrolizumab 
or 180 days after last dose of docetaxel 
Characteristics Pembro-
lizumab 
2mg/kg 
(n = 344) 
Pembro-
lizumab 
2mg/kg  
(n = 346) 
Docetaxel 
75mg/m² 
(n = 343) 
Pembro-
lizumab 
2mg/kg 
PD-L1 ≥50% 
(n = 139) 
Pembro-
lizumab 
10mg/kg 
PD-L1 ≥50% 
(n = 151) 
Docetaxel 
 
 
PD-L1 ≥50% 
(n = 152) 
Median age (range), 
years 
63  
(56–69) 
63 
(56–69) 
62 
(56–69) 
62  
(56–69) 
64  
(58–70) 
60  
(54–69.5) 
Male sex, % 62 62 61 58 59 61 
Histology, %  
Squamous 
Non-squamous 
Other 
Unknown  
 
22 
70 
3 
6 
 
23 
71 
2 
5 
 
19 
70 
3 
8 
 
21 
68 
3 
8 
 
27 
65 
3 
5 
 
17 
73 
3 
7 
Smoking status 
Former or current 
Never 
Unknown 
 
81 
18 
1 
 
82 
17 
<1 
 
78 
20 
2 
 
81 
19 
1 
 
81 
19 
0 
 
74 
22 
3 
Stable brain 
metastases 
16 14 14 23 15 15 
ECOG performance 
status1, % 
0 
1 
2 
 
 
33 
67 
1 
 
 
35 
65 
<1 
 
 
34 
65 
<1 
 
 
34 
65 
1 
 
 
31 
69 
0 
 
 
32 
67 
1 
EGFR status 
Wild-type 
Mutant 
Unknown 
 
85 
8 
7 
 
83 
9 
8 
 
86 
8 
6 
 
86 
6 
8 
 
84 
9 
7 
 
86 
8 
6 
PD-L1-TPS ≥50%, % 40 44 44 100 100 100 
ALK translocation 
No  
Yes 
Unknown 
 
89 
1 
10 
 
88 
1 
11 
 
90 
1 
9 
 
86 
1 
13 
 
87 
1 
12 
 
90 
1 
9 
Line of previous 
systemic therapy, % 
1 
2 
≥3 
 
 
71 
19 
8 
 
 
68 
20 
10 
 
 
69 
22 
8 
 
 
70 
22 
7 
 
 
69 
17 
11 
 
 
72 
16 
10 
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Title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer [20] 
Study identifier NCT01905657, 2012-004391-19, KEYNOTE-010 
 Type of previous 
systemic therapy, % 
Chemo2 
Immuno 
EGFR tyrosine 
kinase 
ALK inhibitor 
 
 
97 
1 
12 
 
1 
 
 
97 
<1 
16 
 
1 
 
 
99 
<1 
14 
 
1 
 
 
99 
1 
10 
 
2 
 
 
97 
1 
13 
 
2 
 
 
98 
0 
14 
 
1 
Data are median (IQR) or n (%).  
Abbreviations: EGFR = epidermal growth factor receptor, ALK = anaplastic lymphoma kinase,  
ECOG = Eastern Cooperative Oncology Group, TPS = tumour proportion score.  
1 For five of the six patients who had an ECOG performance status ≥2 during screening,  
the score improved to 1 by the time the patients were randomly allocated to treatment. 
2 Patients whose disease progressed within 1 year of completing platinum-based therapy were also eligible. 
 
 
